Unión Europea -
español -
EMA (European Medicines Agency)
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - los sueros inmunes e inmunoglobulinas, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ver secciones 4. 4 y 5.
Perú -
español -
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)
ronapreve 120 mg/ml + 120 mg/ml solucion inyectable y para perfusion
roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 120mg/ml + 120mg/ml - por vial 11.10 ml - - casirivimab y imdevimab
Perú -
español -
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)
ronapreve 300mg/2,5ml + 300mg/2,5ml solucion inyectable y para perfusion
roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 300mg +300mg - por vial 300.00 mg - - casirivimab y imdevimab